Meeting
2016 ASCO Annual Meeting
5-year follow up for 72 metastatic melanoma patients treated with eltrapuldencel-T (CLBS20) vaccine.
Authors
Robert O. Dillman
Caladrius Biosciences, Inc., Irvine, CA
Robert O. Dillman , Carol DePriest
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Vaccines
Clinical Trial Registration Number
NCT00948480 & NCT00436930
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3090)
DOI
10.1200/JCO.2016.34.15_suppl.3090
Abstract #
3090
Poster Bd #
412
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines.
First Author: Robert O. Dillman
Poster
2014 ASCO Annual Meeting
A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer.
First Author: Rina Khatri Patel
Poster
2014 ASCO Annual Meeting
Long-term survival for patients with detectable metastatic melanoma at time of treatment with patient-specific tumor stem cell vaccines.
First Author: Robert Owen Dillman
Poster
2013 ASCO Annual Meeting
Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody.
First Author: Katja Schindler